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The xenobiotics such as carcinogens, drugs, or pollutants are chemical substances which are 
not naturally from human bodies. After entering human bodies, the xenobiotics will 
biotransformed into their metabolites by metabolic enzymes, which usually show higher toxicity. 
The reactive metabolites react with macromolecules including DNA, proteins, and lipids in cells 
to form adducts. During metabolism of xenobiotics, reactive oxygen species (ROS) are also 
produced, which would induce oxidative damage on macromolecules. The damaged DNA may 
cause mutations during DNA replication. If the mutations occur at critical genes, such as tumor 
suppressor gene or oncogenes, this would lead to cancers. The damage on proteins will change 
protein functions or provoke an antigen response. One theme of this research is to detect DNA 
oxidative damage on tumor suppressor gene by liquid chromatography and mass spectrometry 
(LC-MS). The other aim of this research is to develop methods to investigate drug induced protein 
damage by LC-MS. 
In this thesis, Chapter 2 describes detection of oxidative sites on exon 7 of p53 tumor 
suppressor gene induced by catechol and Fenton’s reagent. By comparing our results with p53 
database, we correlated these two oxidants with organ specific cancers. Chapter 3 describes an 
analytical method to investigate acetaminophen induced glutathione S-transferase adducts. 
Different metabolic enzymes were employed to monitor the relative amounts of adducts formation. 
Chapter 4 describes a quantitative method for therapeutic monoclonal antibody glycoforms in vivo  
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by LC-MS. Overall, this research work has developed analytical methods to detect DNA and 
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Chapter 1  Introduction 
1.1 Goals and Significance 
Exposure to reactive endogenous or exogenous chemicals can cause significant DNA and 
protein damage in the living cells through the processes of oxidation or adduction. 1 - 3  The 
structurally modified DNA bases increase the probability of polymerase errors during DNA 
replication. If not repaired, mutations will occur which may lead to cancers.4,5 Modification of a 
protein will dysfunction the protein which may lead organ failure.6 
One major class of chemical-derived damage to macromolecules is oxidation. Oxidation of 
DNA occurs continuously in the human body via reactions with reactive oxygen species (ROS), 
e.g., hydroxyl radical (•OH), singlet oxygen (1O2), peroxynitrite (ONOO
-), hydrogen peroxide 
(H2O2), and superoxide (O2•
-). ROS are produced from endogenous processes, like metabolism and 
inflammation, and also by exogenous factors, like UV radiation, air pollution, and tobacco smoke.7 
Reactive oxygen species (ROS) such as hydroxyl radical, singlet oxygen, peroxynitrite, and 
superoxide play important roles in living organisms, e.g. as messengers in cell signaling cascades. 
However, they can also induce cell apoptosis during oxidative stress, featuring unregulated 
accumulation of ROS from endogenous or exogenous processes. 8  Increasing oxidative DNA 
damage levels have been observed in human subject with increase age in coronary heart disease.9,10 
Unrepaired oxidative DNA damage can lead to cardiovascular disease, Parkinson’s disease, 
Alzheimer’s disease, aging and even cancer.11-15 Oxygen-derived radicals are likely lesions that 
induce mutagenesis in hotspot codons in the ras oncogene and the p53 tumor suppressor gene 




Another class of chemical-derived macromolecule damage is drug-induced adduction. One 
mechanism of drug-induced hepatotoxicity is irreversible chemical modification of a protein by a 
chemically reactive metabolite, which then leads to dysfunction of the protein.6 (Scheme 1.2) 
Drug-induced liver injury is the most frequent reason for the withdrawal of an approved drug from 
the market. For approved drugs, at supratherapeutic doses or after long-term usage, drugs can also 
form reactive metabolites and adduct on proteins.19 
The goal of this thesis is to assess the oxidative damage on p53 tumor suppressor gene and 
correlate the damage to specific types of cancers; second, to assess the adducted damage on 
glutathione S-transferase protein to indicate organ failure by drugs. Chapter 1 introduces the 
formation of DNA oxidation and mutations caused by oxidation. The discussion focuses on the 
chemistry and biological significance of DNA oxidation. Also, a brief description about protein 
modifications by metabolites and post-translational modifications is also discussed. Liquid 
chromatography - mass spectrometry (LC-MS) technique on DNA oxidation detection and protein 
modification detection is summarized. In Chapter 2, oxidation sites on exon 7 of p53 tumor 
suppressor gene caused by catechol/Cu2+/NADPH and Fenton’s reagent is located by LC-MS. 
Scheme 1. 1 Pathway of oxidative stress. 
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Chapter 3 describes a protein damage screening method using magnetic beads bioreactors with 
different cytochrome P450 enzymes and LC-MS. Chapter 4 describes a LC-MS quantitative 
method for biotherapeutic monoclonal antibody glycoforms in vivo. 
1.2 Oxidation of DNA 
1.2.1 ROS 
The most common ROS is Hydroxyl Radical (•OH) which can be produced from γ-rays of 
60Co and by Fenton reactions of Fe(II) or Cu(II) ions with hydrogen peroxide.20,21 H2O2 exists in 
human cells, Fe(II) ions are physiologically necessary for iron-containing proteins, and Cu(II) ions 
exist in blood plasma and cell nuclei. Redox cycling of quinone-like metabolites with Cu(II) and 
NADPH can form •OH radical and other ROS. As a simple example, catechol undergoes this type 
of redox cycling that leads to a 2 e-oxidation to o-quinone, which subsequently undergoes two 1 
electron enzymatic reductions back to catechol (Scheme 1.3). ROS including H2O2, O2
•-, and •OH 
have been reported and would amplified by the redox cycling.22,23 Thus, •OH radical is generated 
Scheme 1. 2 Pathway of Protein adducts formation. 
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by multiple sources within human cells, and DNA oxidation by •OH most likely happens 
endogenously and exogenously. 
Another type of ROS is singlet oxygen (1O2) which is produced during photosensitization 
process during which energy is transferred from an excited triplet-state sensitizer to ground-state 
oxygen.24,25 1O2 can also be produced intracellularly by neutrophils during phagocytosis, and 
extracellularly by stimulated macrophages.26,27 
Peroxynitrite (ONOO-) is produced by nitric oxide (NO) reacting with superoxide (O2•
-) in 
vivo, and represents a biologically important oxidant.28,29 It forms under endogenous conditions 
and is linked to amyotrophic lateral sclerosis, atherosclerosis, and neurodegeneration. It also forms 
from exogenous sources such as tobacco smoke, which contains quinone radicals that reduce 
oxygen to O2•
- that can react with NO in the smoke to form peroxynitrite.30,31 
1.2.2 Oxidation Products 
Guanine is the main oxidation target in genes due to having the lowest standard potential (1.3 
V vs. NHE) of all native nucleobases32 and is by far the most frequently oxidized DNA base.33, 
Scheme 1. 3 Redox cycling of quinones with M2+ utilizing electrons from NADPH produce 
ROS that can oxidize DNA. 
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The primary product of guanine oxidation is 8-oxo-7,8-dihydroguanine (8-oxoG), 34 which is a 
major biomarker for oxidative DNA damage.35 8-OxoG has a much lower oxidation potential (0.75 
V vs. NHE) than guanine, and can be more easily oxidized.36 Considerable effort has been devoted 
to identifying the oxidation products of 8-oxoG, and is well accepted that 8-oxoG is not the final 
oxidation product of guanine in DNA.37-39  Imidazolone (Iz) was reported as a direct product of 
guanine oxidation and can be dehydrated to oxazolone (Ox). Other reported oxidation products of 
G include 5-guanidinohydantoin (Gh), spirodihydantoin (Sp), 2,2,4-triaminooxazolone (Oz), 
dehydroguanidinohydantoin (DGh), trioxo-[1,3,5]-triazinane-1-carboxamidine (CAC), cyanuric 
acid (CA), N-nitro-dehydroguanidinohydantoin (NO2-DGh), parabanic acid (PA), oxaluric acid 
(OA), 4-hydroxy-2,5-dioxo-imidazolidine-4-carboxylic acid (HICA), with most resulting from the 
initial 8-oxoG.40-42(Scheme 1.4) 
 




Different oxidation products on DNA may result in different kinds of gene mutations, with 
the caveat that occurrence of the mutation depends on the specificity of efficiency of repair of the 
targeted gene. During normal DNA replication, guanine pairs with cytosine. If guanine is oxidized 
to 8-oxoG, it mispairs with adenine, and thymine pairs with adenine in the next replication, which 
leads a G to T transversion.43,44 However, when guanine is oxidized to Iz, it mispairs with guanine, 
which leads to a G to C transversion.45 Ox, the hydrolysis product of Iz, gives rise to a G to T 
transversion.46,47 Gh causes G to C transversions, Sp stereoisomers cause both G to C and G to T 
transversions, depending on the isomeric forms of the oxidation product. 48  If the resulting 
mutations are located on critical genes, such as tumor suppressor genes or oncogenes and repair is 
not effective, cancers can be promoted.49 
1.3 P53 Tumor Suppressor Gene 
Tumor suppressor genes encode tumor suppressor proteins that control critical processes, such 
as cell growth, cell division, autophagy, and tumor inhibition.50 TP53 (or p53) was confirmed as a 
tumor suppressor gene in the 1980s.51 It encodes the p53 protein that regulates cell cycles and 
inhibits tumor growth. Unrepaired DNA lesions on p53 would lead to mutations. Mutations in the 
p53 tumor suppressor gene are found in 50-60% of human cancers, and some of these correlate 
with oxidatively damaged codon sites.52-54 Oxidation products of guanine pair with bases other 
than cytosine, which leads to mutations. DNA oxidation by ROS is non-random, and may precede 
mutations at the same sites.  
Fenton’s reagent induced base pair changes at mutation hot spot p53 codons 248, 249, 250 in 
human fibroblasts investigated by restriction fragment length polymorphism/polymerase chain 
reaction (RFLP/PCR).55 The DNA sequence containing mutated sites was amplified by PCR. The 
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second G (CGG→CCG) and third G (CGG→CGA) in codons 248 and (AGG→ATG, 
AGG→AGT) in codon 249, and the first C (CCC→ACC) in codon 250 was mutated after the 
Fenton oxidation. 
A yeast reporter system was used to detect change-in-function mutations in p53 gene, which 
were caused by DNA oxidation with ROS generated from polycyclic aromatic hydrocarbons (PAH) 
o-quinones.56 P53 DNA fragment was incubated with PAH o-quinone and redox cycling system 
(NADPH and CuCl2). The yIG397 yeast strain contains an adenine reporter gene under the control 
of p21 promoter. A p53-p21 reporter binding assay was used to measure the incidence of mutation. 
Then, p53 plasmid DNA was recovered from the yeast, and sequenced with S6 (5’-
dCTGGGACAGCCAAGTCTGT3’), R6 (5’-dCCTCATTCAGCTCTCGGAA3’) primers to 
reveal the mutations. 53 yeast colonies were examined, in which 63 mutations were sequenced, 29 
were G to T transversions, and 16 occurred at hot spots of lung cancer such as codon 157 (GTC 
→ ATC), 244 (GGC→GAC), 245 (GGC→TGC), 249 (AGG→ATG, AGG→AGC), and 273 
(CGT→CTT). 
Co-generation of nitric oxide and superoxide induced mutation at codon 248 in the p53 gene.57 
Human bronchial epithelial cells (BEAS-2B) were treated with nitric oxide donor systems and 
harvested 72 h later. The genomic DNA was extracted, purified and subjected to fish-RFLP/PCR 
to detect mutations. Mutations in codon 248 were observed as CGG→TGG, CGG→CAG, and 
CGG→CCG.  
Codon specific mutations in the p53 exon 7 were investigated by ultraviolet B light radiation 
in human skin fibroblasts.58 Fibroblasts were treated with UVB radiation grown for 72 h. Then, 
DNA was extracted and mutations in p53 codons 247-250 were found by the genotypic RFLP-
PCR assay. Mutations occurred in codon 250 (CCC→ACC), codon 249 (AGG→AGT), codon 248 
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(CGG→AGG), and codon 247 (AAC→AAA, AAC→AAT). These base pair changes are most 
likely due to pyrimidine photodimers as premutagenic lesions.  
1.4 Protein Modifications 
1.4.1 By Metabolites 
Protein adducts by carcinogens are considered as surrogates for DNA adducts. The reactive 
metabolites react with proteins by covalently binding nucleophilic amino acid residues.59 The 
target proteins are usually hemoglobin from red blood cells and albumin from blood plasma.60 
BPDE adducted hemoglobin (Hb) and serum albumin (SA) has been investigated61 and 4-ABP-
Hb adducts have been used as a biomarker distinguishing between smokers and nonsmokers.62 
Also, protein adducts formation might disrupt protein structure or function causing damage to 
submembrane organelles, metabolic pathways, or cytological processes, which play a causal role 
in initiating pathophysiological process of chemical-induced nerve cell injury.63 
Drug induced toxicity is another type of protein damage due to drugs. Many drugs are 
oxidative bioactivated to reactive metabolites by enzymes and covalently bind on proteins. The 
mechanisms of toxicity by protein adducts are considered as either changing target protein 
functions or stimulating an immunological response of the host immune system against modified 
proteins.64 The target tissues of protein adducts depend on the location of bioactivation enzymes, 
drug accumulation, and chemical stability of reactive metabolites. Liver is usually the major 
affected organ since most drugs are metabolized in the liver.65 
1.4.2 Post-Translational Modification 
Post-translational modification (PTM) of protein is the process of adding chemical groups to 
its amino acid residues during protein synthesis. It’s important for protein functionalization and 
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cell signaling.66 There are over 200 protein modifications detected with current technologies.67 
Phosphorylation is one of the most common PTM, which is essential for intracellular signaling.68 
Glycosylation is another type of PTM, in which carbohydrate molecules are attached to the 
proteins. Glycosylation can promote protein folding and improve the stability of proteins. 69 
Different glycan structures on therapeutic antibodies would have different clearance rate, which 
may impact the efficiency of antibody drugs.70 There are also types of PTM caused by oxidative 
stress. Carbonylation of protein is one type of PTM because of oxidation, is usually considered as 
a major biomarker of oxidative stress-related diseases.71 Cysteine oxidation is another type of PTM 
by oxidation by producing sulfenic acid (R-SOH), sulfinic acid (R-SO2H), and sulfonic acid (R-
SO3H), which play important roles in cell signaling and protein functions.
72  
1.5 Mass Spectrometry in DNA Oxidation 
Mass spectrometry (MS) has emerged as a powerful modern tool to investigate structurally 
damaged DNA.5 Stable isotope labeling of DNA has been widely used along with MS to examine 
the reactive sites and cytosine methylation on the formation of 8-oxoG and downstream oxidation 
products of reactions with nitrosoperoxycarbonate and riboflavin-mediated photolysis using 
multiple reaction monitoring (MRM).41 Experiments were done on 15N3,
13C1-labeled DNA 
oligodeoxynucleotides synthesized by standard phophoramidite chemistry using a DNA 
synthesizer. 15N3,
13C1-dG phosphoramidite and 
15N3,
13C1-dG phosphoramidite were also 
synthesized and used. Percent oxidation at labeled guanine equals the LC MRM peak area of the 
labeled oxidation product divided by the sum of LC MRM peak areas of labeled and unlabeled 
oxidation products. In this way, the amounts and locations of 8-oxoG and other products formed 
on the DNA strands are revealed. 
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LC-MS/MS approaches have been developed to size and sequence DNA oligonucleotides up 
to 20 bp.73,74 QTOF-MS/MS was employed to detect sequence and agent specificity on the further 
oxidation products of 8-oxodG in DNA oligonucleotides.42,75 Synthesized 8-oxodG containing 
oligonucleotides were oxidized by two oxidants (nitrosoperoxycarbonate and riboflavin-mediated 
photooxidation) to detect the 8-oxodG derived oxidation products. DGh containing 
oligonucleotides were found as the predominant products. The relative amounts of 8-oxodG 
products by nitrosoperoxycarbonate oxidation is not affected by sequences; while products of 
riboflavin-mediated photooxidation of 8-oxodG are sequence dependent. 
1.6 Mass Spectrometry in Protein Modification 
Mass spectrometry is a powerful tool to detect the protein modifications. The protein 
modification events are detected by increases in masses of the modifications. Sites of 
modifications can be identified from mass shifts in fragment ions generated from fragmentation 
(MS/MS) in mass spectrometry.76 The type and sites of modifications are determined by analyzing 
the fragmentation spectra of modified peptides. Usually, a database searching on non-modified 
peptides is performed to identify proteins, then a database searching of modified peptides within 
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Chapter 2  Direct LC-MS/MS Detection of Guanine Oxidations in Exon 7 of the p53 Tumor 
Suppressor Gene 
2.1 Abstract 
Oxidation of DNA by reactive oxygen species (ROS) yields 8-oxo-7,8-dihydroguanosine (8-
oxodG) as primary oxidation product, which can lead to downstream G to T transversion mutations. 
DNA mutations are nonrandom and mutations at specific codons are associated with specific 
cancers, as widely documented for the p53 tumor suppressor gene. Here, we present the first direct 
LC-MS/MS study (without isotopic labeling or hydrolysis) of primary oxidation sites of p53 exon 
7. We oxidized a 32 base pair (bp) double-stranded (ds) oligonucleotide representing exon 7 of the 
p53 gene. Oxidized oligonucleotides were cut by a restriction endonuclease to provide small 
strands and enable positions and amounts of 8-oxodG to be determined directly by LC-MS/MS. 
Oxidation sites on the oligonucleotide generated by two oxidants, catechol/Cu2+/NADPH and 
Fenton’s reagent, were located and compared. Guanines in codons 243, 244, 245 and 248 were 
most frequently oxidized by catechol/Cu2+/NADPH with relative oxidation of 5.6 % 7.2 %, 2.6 %, 
and 10.7 %, respectively. Fenton’s reagent oxidations were more specific for guanines in codons 
243 (20.3 %) and 248 (10.4 %). Modeling of docking of oxidation agents on the ds-oligonucleotide 
were consistent with the experimental codon oxidation sites. Significantly, codons 244, 248 are 
mutational “hotspots” in non-small cell and small cell lung cancers, supporting a possible role of 





Reactive oxygen species (ROS) such as hydroxyl radical (•OH), singlet oxygen (1O2), 
peroxynitrite (ONOO-) and superoxide (O2•-) play important roles in living organisms, e.g. as 
messengers in cell signaling cascades. However, they can also induce cell apoptosis during 
oxidative stress,1  featuring unregulated accumulation of ROS from endogenous or exogenous 
processes. Oxidative stress likely plays roles in aging, cardiovascular disease, Parkinson’s disease, 
and cancer.2-6 
One source of ROS is oxidation of transition metals by H2O2, to produce 
•OH, which is 
usually called Fenton’s reaction, especially when involving ferrous ions.7-9 Another source of ROS 
is redox cycling of quinones and other metabolites involving Cu2+ and NADPH. 10 - 14  When 
chemicals or their metabolites lead to DNA damage, they are referred to as genotoxic. Catechol, a 
model for quinoid metabolites, undergoes redox cycling in the presence of Cu2+ and NADPH that 
leads to a 2-electron oxidation to o-quinone, which subsequently undergoes two 1-electron 
enzymatic reductions back to catechol by NADPH. ROS including H2O2, O2
•-, and •OH are formed 
in these redox cycles (Scheme 2.1), and can oxidize DNA in vitro.15,16 Also, polycyclic aromatic 
hydrocarbon (PAH) o-quinones are implicated as causes of mutations in tumor suppressor genes, 
and are known risk factors for lung cancer.17 
Guanine is the main oxidation target in genes due to having the lowest redox potential of the 
DNA nucleobases (1.3 V vs. NHE).18,19 The primary oxidation product of deoxyguanosine is 8-
oxo-7,8-dihydrodeoxyguanosine (8-oxodG), which can lead to G to T transversion mutations 
during DNA replication.20,21 Cancer may result when such mutations occur at tumor suppressor 
genes or oncogenes.22,23 
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Tumor suppressor genes provide cancer protection by coding for proteins that inhibit cell 
proliferation and tumor development.24 TP53 (or p53) was identified as a tumor suppressor gene 
in the 1980s.25 It encodes p53 protein that regulates cell cycle and inhibits tumor growth. Mutations 
in p53 genes are found in > 50% of all human cancers. 26 - 28  Extensive databases document 
mutations found at specific p53 codons from human tumors and cancer cell lines, and show that 
many mutations are well-correlated with specific cancers. Most p53 mutations occur at exons 5-
8.29 E.g. highly mutated codons 157, 158, 248, 249 appear in lung cancers, mutated codons 175, 
248, 273 are found in breast cancer, and mutated codons 175, 248, 282 occur in liver cancer.30,31 
Thus, DNA oxidation at specific sites that lead to mutations at the same sites may be possible to 
correlate with specific cancers. 
Early work in p53 gene oxidation employed gel electrophoresis of DNA fragments. The 
structure of guanine oxidation products was not addressed, and most studies focused on the 
resulting mutations. Both guanine residues (AGG→ATG, AGG→AGT) in codon 249 mutated to 
thymine as a result of Fenton oxidation in human fibroblasts.32 Oxidation of human skin fibroblasts 
by UVB light (280-320 nm) caused G to T mutations at the third position of codon 249 




(AGG→AGT).33 PAH-induced oxidation of p53 has been observed at hot spots associated with 
lung cancer, including codons 245 (GGC→TGC), 249 (AGG→ATG), 273 (CGT→CTT).17 
Mass spectrometry (MS) is a powerful tool to detect structurally damaged DNA.34 LC-
MS/MS approaches have been developed to size and sequence DNA oligonucleotides up to 20 
bp.35 ,36 QTOF-MS/MS was employed to detect sequence and agent specificity on the further 
oxidation products of 8-oxodG in DNA oligonucleotides.37,38 In that study, synthesized 8-oxo-dG 
containing oligonucleotides were oxidized to detect the 8-oxodG derived oxidation products, and 
standard oligonucleotides were not used. Stable isotope labelling of DNA has been widely used 
with mass spectrometry to examine the reactive sites and cytosine methylation on the formation of 
8-oxodG and downstream oxidation products of reactions with nitrosoperoxycarbonate and 
riboflavin-mediated photolysis. 39  This approach detected the amount of 8-oxodG and other 
products formed, but isotopic labelling syntheses and enzymatic oligonucleotide digestion are 
required. 
To investigate reactive sites, the positional isomeric modified oligonucleotides must be 
separated. Harsch et al. reported separation of isomeric benzo[c]phenanthrene diol epoxide 
adducted HRPT gene sequence by using ammonium acetate as ion-pairing reagent.40 Xiong et al. 
identified nine isomeric (±)-anti-7r,8t-dihydroxy-9t,10-epoxy-7,8,9,10-tetrahydro-benzo[a]pyrene 
adducted oligonucleotides using ion pair reagent triethylammonium bicarbonate (TEAB). 41 
Sharma et al. used TEAB to separate oligonucleotides adducted by N-acetylaminofluorene, N-
hydroxy-4-aminobiphenyl and (±)-anti-benzo[a]pyrene diol epoxide to investigate the site 
selectivity.42,43 All these are adduction modification, but there is merely report on investigating 
DNA oxidation sites. 
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We previously described a restriction enzyme-assisted LC-QTOF MS/MS oligonucleotide 
sequencing methodology to detect covalent adduction on ds-oligonucleotides longer than 20 base 
pair (bp).44 We used this approach to evaluate reaction products of oligonucleotides with the diol 
epoxide metabolite of benzopyrene (B[a]P) and examined the effect of cytosine methylation on 
adduct reaction kinetics of exon 7 of the p53 gene.45 In the present paper, we tailor this approach 
to directly detect 8-oxodG formation in oxidized ds-DNA strands. We apply the method to the 32 
bp exon 7 ds-oligonucleotide fragment of the p53 gene, representing p53 codons 242 to 253 
(Scheme 2.2). Ion pairing reagent TEAB was used to separate positional isomeric oxidative 
oligonucleotides. The primary products of exon 7 oligonucleotide from catechol/Cu2+/NADPH and 
Fenton’s reagent oxidation were compared. Analysis of >20 bp oligonucleotides is facilitated by a 
restriction enzyme that cuts the oligonucleotide into smaller fragments suitable for MS/MS 
sequencing. Using this approach, Fenton’s reagent oxidized G at codons 243 and 248; the catechol 
system oxidized guanines at codons 243, 244, 245, and 248, correlating with lung cancer mutation 
hot spots at codons 245, 248. The reacting guanines in codons 245 and 248 are C-phosphate-
Guanine (CpG) sites, and the guanine in codon 248 is also the most reactive towards SN2 reactions 
with B[a]P diol epoxide.45 The p53 oxidation sites have been uncovered in a purely chemical 
reaction, and this is of course much less complex than in vivo in humans. However, we find that 
the most chemically reactive p53 codons present correlations to mutation sites found in tumors. 
  
Scheme 2. 2 Exon 7 of p53 gene showing reactive codons in color. Arrows show cut points for 
restriction enzyme Nla III, and resulting fragments obtained. 
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2.3 Experimental Section 
2.3.1 Chemicals and Materials 
Custom oligonucleotides were from MilliporeSigma. Catechol, D-glucose 6-phosphate 
sodium salt (G6P), β-nicotinamide adenine dinucleotide phosphate sodium salt hydrate (NADP+), 
glucose-6-phosphate dehydrogenase (G6PDH), CuCl2, MgCl2, FeSO4
.7H2O, H2O2 solution (30 % 
w/w), triethylammnium bicarbonate (TEAB, 1.0 M, pH 8.4-8.6), 3-nitrobenzyl alcohol, 
chloroform-isoamyl alcohol mixture (24:1), phenol-chloroform-isoamyl alcohol mixture (25:24:1) 
were from MilliporeSigma. Restriction enzyme, Nla III was from New England Biolabs Inc. 
2.3.2 Oligonucleotide Oxidation and Restriction Enzyme Cutting 
100 μg of oligonucleotides in 50 mM pH 7.2 Tris buffer with 50 mM NaCl were incubated 
in a total volume of 200 μL with 1 mM catechol, 50 μM CuCl2, and NADPH regeneration system 
(10 mM G6P, one unit G6PDH enzyme, 0.8 mM NADP+, 1 mM MgCl2) at 37 ℃ for 12 hours. 
Alternatively, 100 μg of oligonucleotides in 10 mM pH 5.5 acetate buffer with 50 mM NaCl in a 
total volume of 200 μL were incubated with Fenton’s reagent containing 0.1 mM FeSO4 and 40 
mM H2O2 at 37 ℃ for 4 hours with constant stirring. Amicon Ultra-0.5 3K centrifugal filters from 
MilliporeSigma were used to remove excess catechol, NADPH system, and FeSO4 products. The 
reaction mixture was put into the filter vial and centrifuged at 13,000 rpm for 30 min. Ds-
oligonucleotide fragments were retained on the filter, which was then reversed, put into a new vial 
and centrifuged at 13,000 rpm for 30 min to collect the approximately 50 μL of ds-oligonucleotide. 
Then, 15 μL (150 units) of restriction enzyme Nla III, 20 μL of 10 × NE buffer (New England 
Biolabs, 1× buffer contains 50 mM potassium acetate, 20 mM tris-acetate, 10 mM magnesium 
acetate, 100 ug/ml BSA, pH 7.9) and 115 μL of pure water were added to the reacted 
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oligonucleotide solution, and this solution was incubated 37 ℃ for 12 hours to cut oligonucleotides 
into smaller fragments. 
2.3.3 Removal of Enzymes and Salts 
200 μL of phenol/chloroform/isoamyl alcohol (25:24:1) was added to the mixture from the 
above process. The mixture was shaken for 15 min, then centrifuged at room temperature for 10 
min. Then, the upper aqueous solution was carefully transferred to a fresh tube for subsequent 
extraction. The solution was extracted with phenol/chloroform/isoamyl alcohol (25:24:1) three 
times, and chloroform/isoamyl alcohol (24:1) twice. The resulting aqueous oligonucleotide 
solution was about 200 μL. 
100 μL of 7.5 M ammonium acetate was added to the DNA solution for ethanol precipitation, 
then 700 μL of cold ethanol was added to the mixture. The solution was mixed well, and stored at 
-20 ℃ for 1 hour, followed by centrifugation at 4 ℃ for 30 min. The supernatant was carefully 
removed, then 1 mL of 70% cold ethanol in water was used to wash the pellet, which was then 
dried under N2 and dissolved in 100 μL of HPLC-grade water. This solution was heated at 90 ℃ 
for 15 min and cooled rapidly to convert ds- to ss-oligonucleotides, then stored at -20 ℃. 
2.3.4 UPLC-QTOF MS/MS Analysis 
A Dionex Ultimate 3000 UPLC with a Gemini C-18 column (150 × 0.5 mm, 3 μm particle 
size) was used with mobile phases 25 mM triethylammonium bicarbonate (TEAB, solvent A) and 
methanol (solvent B).44 A gradient of 15% B for 2 min followed by increasing from 15 % B to 
20% B over 36 min, then back to 15% B for another 2 min at flow rate 8 μL/min was used. The 
UHPLC was interfaced to an AB Sciex QSTAR Elite mass spectrometer in negative ion mode with 
a -4500 V ion spray voltage, -60 V declustering potential at 300 ℃. 0.1% of m-nitrobenzyl alcohol 
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was infused 4 μL/min to mix with the LC flow post-column using a three way connector before 
entering the QSTAR to enhance oligonucleotide charging and signal intensity. 46  The ss-
oligonucleotides were analyzed by time of flight scan mode for sizing unoxidized and oxidized 
fragments. Product ion scan mode was used for sequencing oxidized fragments at -40 eV collision 
energy. In most cases, analysis was restricted to singly oxidized oligonucleotides. 
2.3.5 Molecular Modelling 
The standard B-DNA form of 32 bp p53 exon 7 ds-oligonucleotide was modelled using 
online DNA sequence to structure tool47 and solvated using CHIMERA software48 . An Amber 
solvation model was used with appropriate box size to accommodate water molecules.45 Autodock 
4.2.6 was used for docking.49 Ligands (Fe2+, Fe3+, H2O2, •OH, catechol, benzoquinone, Cu(I)OOH) 
were imported into the model software. A Lamarckian genetic algorithm (LGA) was used in 




2.4.1 Method Development 
The 32 bp exon 7 p53 fragment was oxidized with catechol or Fenton’s reagent, then the 
oxidized ds-oligonucleotide were cut to smaller size suitable for LC-MS/MS. Restriction enzyme 
Nla III cuts ds-DNA after the sequence CATG (no cleavage after CATG in Fragment 1, due to no 
bases after G in the complimentary strand), resulting in two ds fragments of 13 and 19 bases, but 
leaving unpaired CATG at the ends (Scheme 2.2). After cutting, heat treatment is used to convert 
all ds-oligonucleotides to single strands. 
Our focus was to identify the primary oxidation sites on exon 7, so we developed conditions 
to determine 8-oxodG sites in singly oxidized fragments. Our reaction conditions yielded 8-oxodG 
as the only oxidation product. If a single dG is oxidized to 8-oxodG, the mass of the reacted ss-
oligonucleotide increases by 15.999. The identity of each 8-oxodG-containing oligonucleotide was 
determined by comparing the measured m/z of the oxidized oligonucleotide to the expected m/z 
of the corresponding unreacted species calculated using Mongo Oligo Mass Calculator, v2.08.50 
M/z values for the four unoxidized and oxidized oligonucleotide fragments are shown in Table 2.1. 
For example, m/z 1002.4 was observed for unoxidized Fragment 1 (Scheme 2.2) with z = -4, and 
the 8-oxodG-containing Fragment 1 had m/z = 1006.4 (z =-4). TOF MS spectra of the four 




aMolecular weight based on Mongo Oligo Mass Calculator, v2.08. bBased on the ion with different 
























5818.956 5834.955 969.0(-6) 971.7(-6) 




7107.182 7123.181 1183.7(-6) 1186.4(-6) 
Table 2. 1 Mass-to-charge ratios of four oligonucleotide fragments containing 8-oxodG 
Scheme 2. 3 Collision induced dissociation (MS/MS) of DNA fragments resulting in the 
generation of wn and an-bn ions. 
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Collision-induced dissociation (CID) provided information on the sequence of oxidized 
oligonucleotide products by fragmentation of the phosphodiester backbone (Scheme 2.3),  forming 
an-bn and wn ions.
51,52 The position of 8-oxodG was determined by detecting the difference in m/z 
values of the an-bn and wn ions of corresponding unoxidized and oxidized oligonucleotides. 
 
2.4.2 Oxidation by Catechol/Cu2+/NADPH 
Catechol is an industrial chemical and a major component of tobacco smoke,53  and is 
classified as a group 2B carcinogen.54,55  In the presence of Cu2+ and an enzymatic NADPH 
regenerating system, redox cycling of catechol, semiquinone radical, and benzoquinone produces 
ROS, which oxidize dG to 8-oxodG in DNA (Scheme 2.1).15,16,56 
  
Figure 2. 1 Negative-ion ESI-MS of singly oxidized fragments (A) oxidized Fragment 1, m/z 
1006.4 (-4), (B) oxidized Fragment 2, m/z 971.7 (-6), (C) oxidized Fragment 3, m/z 917.1 (-3), 




Figure 2. 2 LC-QTOF mass spectrometry of Fragment 1 (Scheme 2.2) from Exon 7 oxidized 
by Catechol/Cu2+/NADPH. (A) Extracted ion chromatogram for m/z 1006.4 representing z=-4 
of singly oxidized products. (B) CID analysis of m/z 1006.4 for peak 1 eluting at 13.6 min and 
(C) CID analysis of peak 2 eluting at 14.9 min. 
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Figure 2.2A shows an extracted ion chromatogram (XIC) of a selected ion of oxidized exon 
7 Fragment 1 (Scheme 2.2) with m/z 1006.4 representing 8-oxodG-containing Fragment 1 with 
z=-4. (Most intense charge state ion was used to present XIC.) There are four major peaks in the 
chromatogram suggesting that four positional isomers for singly oxidized Fragment 1 were formed 
with retention times 13.6 min, 14.9 min, 16.2 min, and 17.9 min. The CID spectrum of fragment 
ion 1006.4 for peak 1 is shown in Fig. 2.2B and for peak 2 in Fig. 2.2C. 
Figure 2.2A shows an extracted ion chromatogram (XIC) of a selected ion of oxidized exon 
7 Fragment 1 (Scheme 2.2) with m/z 1006.4 representing 8-oxodG-containing Fragment 1 with 
z=-4. (Most intense charge state ion was used to present XIC.) There are four major peaks in the 
chromatogram suggesting that four positional isomers for singly oxidized Fragment 1 were formed 
with retention times 13.6 min, 14.9 min, 16.2 min, and 17.9 min. The CID spectrum of fragment 
ion 1006.4 for peak 1 is shown in Fig. 2.2B and for peak 2 in Fig. 2.2C. 
Differences in a-b and w ions between unoxidized and oxidized Fragment 1 were used to 
locate the oxidation sites (i.e. 8-oxodG), as used previously for metabolite adduction sites.35,36,44,57 
MS/MS spectrum for Peak 1 of singly oxidized Fragment 1 (Fig. 2.2B) shows increase in mass of 
ions from a6-b6 to a8-b8 compared to unoxidized Fragment 1. This indicates that the fifth guanine 
was oxidized to 8-oxodG, CATGGoxGCGGCATG. The MS/MS spectrum for peak 2 of singly 
oxidized Fragment 1 (Fig. 2.2C) shows an increase in mass of all ions from a9-b9 compared with 
that of the unoxidized Fragment 1. This shows that the eighth guanine was oxidized to 8-oxodG, 
CATGGGCGoxGCATG, and is confirmed by increases in mass of w ions from w6 ion. Similar 
analysis of the third and the fourth peaks, revealed that peak 3 indicates oxidation of the sixth 
guanine (CATGGGoxCGGCATG) and peak 4 represents oxidation of the fourth guanine in 
CATGoxGGCGGCATG) (Fig. 2.3). 
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Singly oxidized Fragment 2 gave m/z of 971.7 at z= -6 (Fig. 2.1B). The XIC of m/z 971.7 
(Fig. 2.4A) showed only one major peak, which indicated that only one base on Fragment 2 was 
oxidized during the reaction. MS/MS spectra for singly oxidized Fragment 2, m/z 971.7, (Fig. 2.4B) 
shows increase in mass of all ions from a6-b6, a7-b7, suggesting that the fifth guanine was oxidized, 
AACCGoxGAGGCCCATCCTCA. This is confirmed by increase in mass of w15 and w16 for w 
ions. All ions below w14 gave the same m/z values as the unoxidized fragment. 
Two unknown peaks were found in oxidized Fragments 1 (20.3 min) and 2 (28.7 min) after 
catechol/Cu2+/NADPH oxidation (Fig. 2.2A, 2.4A). They are also positional isomers of oxidized 
Fragments 1 and 2, but were not intense enough for reliable identification. 
Similar analyses were done on oxidized complimentary strands of Fragments 3 and 4. 
Results identified oxidized Fragment 3 with m/z 917.1, z = -3 (Fig. 2.1C) and oxidized Fragment 
4 with m/z 1186.4 (Fig. 2.1D), z = -6 (Table 2.1). MS/MS spectra are shown in Fig. 2.5, 2.6. In 
Fragment 3, the third and the last guanines were oxidized (CCGoxCCCATG, CCGCCCATGox), 
and the fourth guanine in Fragment 4 was oxidized (TGAGoxGATGGGCCTCCGGTTCAG). 
Oxidation sites for all the fragments are summarized in Table 2.2. 
We estimated the relative abundance of specific oxidized fragments by comparing areas 
under extracted ion chromatograms of oxidized fragments to those of unoxidized fragments (Fig. 
2.7), assuming that oxidized and unoxidized fragments have similar MS ionization efficiencies.44 
Take oxidized Fragment 1 by Catechol/Cu2+/NADPH as an example, Figure 2.2A is the XIC of 
oxidized Fragment 1 1006.4 (-4), Figure 2.7A is the XIC of unoxidized Fragment 1 1002.4 (-4). % 
oxidized of Peak 1 (CATGGoxGCGGCATG) representing guanine in codon 244 was calculated 
by dividing the peak area under peak 1 in Figure 2.2A by the peak area under the peak (unoxidized 
Fragment 1) in Figure 2.7A. % oxidized of Peak 2, 3, 4 of oxidized Fragment 1 and oxidized 
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Fragment 2 were also calculated using the method described above. The relative amounts of 
oxidation in the 32 bp fragment were estimated (Table 2.2). Ratios of relative amounts of oxidation 




Figure 2. 3 (A) CID analysis of oxidized Fragment 1 by Catechol/Cu2+/NADPH, m/z 1006.4 
for peak 3 eluting at 16.2 min and (B) CID analysis of peak 4 eluting at 17.9 min. 
Representative CID fragmentation of a 8-oxodG containing oligonucleotide confirmed the 









Figure 2. 4 LC-QTOF mass spectrometric analysis of 8-oxodG containing Fragment 2 
oxidized by catechol/Cu2+/NADPH. (A) Extracted ion chromatogram for fragment m/z 
971.7, z = -6 of singly oxidized Fragment 2. (B) CID analysis of oxidized Fragment 2, 




Figure 2. 5 (A) Extracted ion chromatogram for fragment m/z 917.1 representing -3 charge of 
singly oxidized Fragment 3 by Catechol/Cu2+/NADPH. (B) CID analysis of oxidized Fragment 
3, m/z 917.1 for peak 1 eluting at 8.8 min and (C) CID analysis of peak 2 eluting at 10.0 min. 
Representative CID fragmentation of an 8-oxodG containing oligonucleotide confirmed the 






Figure 2. 6 (A) Extracted ion chromatogram for fragment m/z 1186.4 representing -6 charge 
of singly oxidized Fragment 4 by Catechol/Cu2+/NADPH. (B) CID analysis of oxidized 
Fragment 4, m/z 1186.4 for the peak eluting at 33.1 min. Representative CID fragmentation 




2.4.3 Oxidation by Fenton’s Reagent 
Deoxyguanosine in DNA is easily oxidized to 8-oxodG by Fenton’s reagent. The active 
oxidant in Fenton’s reagent is thought to be •OH,58,59 and oxidation products of 8-oxodG have also 
been identified.9,60,61 We found none of these overoxidation products under our conditions. 
Oxidation products of p53 exon 7 by Fenton’s reagent revealed several differences from 
oxidation by catechol/Cu2+/NADPH. Fig. 2.8A shows there is only one major peak in the extracted 
ion chromatogram (XIC) of singly oxidized Fragment 1, indicating only one base was oxidized. 
The MS/MS spectrum for singly oxidized Fragment 1 (Fig. 2.8B) shows an increase in mass of all 
ions from a5-b5 to a7-b7 compared to the unoxidized fragment. This indicates that the fourth guanine 
Figure 2. 7 Extracted ion chromatogram for (A) fragment m/z 1002.4 representing -4 charge of 
unoxidized Fragment 1; (B) fragment m/z 969.0 representing -6 charge of unoxidized Fragment 
2; (C) fragment m/z 911.8 representing -3 charge of unoxidized Fragment 3; (D) fragment m/z 
1183.7 representing -6 charge of unoxidized Fragment 4 after Catechol/Cu2+/NADPH treatment. 
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was oxidized to 8-oxodG, CATGoxGGCGGCATG, confirmed by increased mass of w ions above 















Figure 2. 8 LC-QTOF mass spectrometric analysis of 8-oxodG containing Fragment 1 
oxidized by Fenton’s reagent. (A) Extracted ion chromatogram (XIC) for fragment m/z 
1006.4 representing -4 charge of singly oxidized Fragment 1. (B) CID analysis of oxidized 
Fragment 1, m/z 1006.4 for peak eluting at 17.9 min. 
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Oxidized Fragment 2, and Fragment 4 gave similar results as catechol/Cu2+/NADPH 
oxidation (Fig. 2.9A, 2.9C). For Fragment 3 (Fig. 2.9B), there is only one major peak for the 
oxidized Fragment 3. Results are summarized in Table 2.2. The relative amounts of oxidation by 
Fenton’s reagent were also estimated (Table 2.2) by comparing areas under extracted ion 
chromatograms. Ratio of relative amounts of oxidation for codons 248/243 was 0.5. 
Figure 2. 9 Extracted ion chromatogram for (A) fragment m/z 971.7 representing -6 charge 
of singly oxidized Fragment 2; (B) fragment m/z 917.1 representing -3 charge of singly 
oxidized Fragment 3; (C) fragment m/z 1186.4 representing -6 charge of singly oxidized 
Fragment 4 by Fenton’s reagent. 
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a Small cell lung cancer. b Non-small cell lung cancer. c Hepatocellular carcinoma (HCC). d 
Colorectal cancer. e skin cancer. 
 
  
Table 2. 2 Catechol/Cu2+/NADPH and Fenton’s reagent oxidation results on fragments of p53 
exon 7 compared to mutation sites from the p53 database. 
   LC-MS/MS Data 









CATG Gox GCGGCATG 244 
(3.2) 
244a 
  CATGGGC Gox GCATG 245 
(2.6) 
245b,d 
  CATGG Gox CGGCATG 244 
(5.0) 
244a 











Complementary strands    
 Fragment 3 CCGCCCATG CC Gox CCCATG 
CCGCCCAT Gox 
 
    





















Complementary strands    
 Fragment 3 CCGCCCATG CC Gox CCCATG  








2.4.4 Modelling of Oxidant Binding 
In DNA oxidation mediated by catechol, NADPH and Cu2+, molecular oxygen is reduced to 
O2
•- and H2O2, and catechol reacts with Cu
2+ yielding Cu+ and benzoquinone (Scheme 2.1). Also, 
Cu+ reacts with H2O2 to form •OH radical and Cu(I)-hydroperoxyl complex (Cu(I)OOH), which 
may lead DNA strand breaks. In Fenton’s reagent oxidation, Fe2+ reacts with H2O2 to form Fe
3+ 
ions and •OH radical. To gain insight into the codon specificity of the oxidations, molecular 
modelling was done with AutoDock 4.2.6, by docking each possible involved species (Fe2+, Fe3+, 
H2O2, •OH, catechol, benzoquinone, and Cu(I)OOH) with the B-DNA form of the exon 7 ds-
oligonucleotide. Parameters were set with 25,000,000 evaluations and 50 docked conformations 
for an individual docking computation. Examples of preferred Fe2+ binding site on exon 7 from 
this analysis is shown in Figure 2.10, and preferred catechol sites in Figure 2.11. The preferred 
binding positions and binding free energies (ΔGb) were estimated from this analysis. ΔGb values 
were used to calculate relative apparent binding constants from lnKb=-ΔGb/RT, where R is the 
ideal gas constant and T is temperature in Kelvins. (Table 2.3) For Fe2+, 35 out of 50 docked 
conformations were between the fourth and fifth guanines in Fragment 1 (Fig. 2.10), but the 
binding is quite weak. For catechol, preferred binding was found at multiple positions, including 
Figure 2. 10 Model of Fe2+ docked at preferred site (arrow) near reactive guanine in the 
B form of the 32 bp exon 7 p53 fragment. 
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the fourth, fifth, sixth and eighth, and thirteenth guanines (Fig. 2.11) and the binding is stronger. 
Results for all possible ROS are listed in Table 2.3. 
The two unknown peaks in oxidized Fragment 1 (20.3 min) and Fragment 2 (28.7 min) from 
catechol-mediate oxidation (Fig. 2.2A, 2.4A) were not intense enough for reliable identification. 
However, docking results (Fig. 2.11D) are consistent with the possibility that the thirteenth 
guanine was oxidized in Fragment 1. and G in codon 249 was probably oxidized in Fragment 2 




Figure 2. 11 Models of catechol in yellow docking near reactive guanines in the B form of the 
32 bp exon 7 p53 fragment showing catechol docked (arrows) (A) with the fourth and fifth 




Table 2. 3 Computed binding positions, numbers of docked confirmations, binding free energies, 
and binding constants of possible ROS on the 32 bp fragment of exon 7 p53 gene. 











4-5 243 35 0.04 0.94 
6-7 244 15 0.04 0.94 
Catechol 
15 247 27 -4.02 6.9×102 
13 246 8 -3.64 3.7×102 
4 243 2 -3.31 2.2×102 
16 248 1 -3.36 2.4×102 
9-10 245 8 -3.53 3.1×102 
10 245 1 -3.62 3.6×102 
7-8 245 2 -3.72 4.2×102 
6-7 244 1 -3.27 2.0×102 
Iron (III) 
4-5  243 21 0.04 0.937 
5-6  244 3 0.04 0.937 
6-7 244 26 0.04 0.937 
.OH 
17 248 22 -1.9 2.18×10 
Phosphate between 8-
9  
245 28 -1.9 2.18×10 
Superoxide 
17-18 248 44 -3.24 1.92×102 
6  244 5 -3.06 1.44×102 
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12 246 1 -2.84 1.00×102 
H2O2 
6  244 3 -3.21 1.83×102 
17  248 2 -3.33     2.24×102 
Phosphate between 3-
4  
243 1 -3.13 1.61×102 
Phosphate between 8-
9  
245 27 -3.13 1.61×102 
Phosphate between 
17-18 
248 3 -3.08 1.48×102 
Phosphate between 9-
10  
245 9 -3.33 2.24×102 
Phosphate between 
13-14 
246 5 -3.52 3.05×102 
Quinone 
13  246 9 -3.97 6.33×102 
7-8  245 10 -4.19 8.98×102 
15  247 31 -4.63 1.84×103 
Cu(I)OOH 
7-8  245 1 -2.73 8.39×10 
16-17 248 2 -3.01 1.33×102 
15  247 10 -2.73 8.39×10 
6     244 11 -2.84 1.00×102 
8  245 11 -2.72 8.31×10 
18  248 11 -2.99 1.28×102 





Results above demonstrate successfully development of LC-MS/MS methodology to 
directly locate primary oxidation sites in ds-oligonucleotides of >20 bp without labeling or 
hydrolysis. This is the first report directly identifying multiple oxidation sites in an intact ds-
oligonucleotide. The restriction enzyme assisted methodology is simple, reliable, relatively rapid, 
and facilitates direct detection and mapping of modified sites. It does not require stable isotope 
labelling or DNA hydrolysis. 
Results reveal that primary oxidation sites involve only guanines on the p53 exon 7 
oligonucleotide. This is consistent with guanines as the most easily oxidized of the DNA 
nucleobases. In general, reactivity of specific guanines within the exon 7 p53 ds-fragment are 
influenced additionally by neighboring bases and to some extent by secondary structure of the 
oligonucleotide.45 The most frequently oxidized guanine by catechol/Cu2+/NADPH in the present 
study was in codon 248 (11%, Table 2.2), which correlates with codon 248 as a major mutation 
hot spot in many cancers.30 Guanines within codons 243, 244 and 245 were oxidized to a smaller 
extent. Thus, there is a quantitative correlation between the high reactive frequency of codon 248 
in the p53 exon 7 oligonucleotide with its high mutated frequency in cancers using an oxidation 
process that mimics oxidations mediated by redox active metabolites (Scheme 2.1).10-14,17 However, 
in Fenton’s reagent oxidation, which may or may not have a directly analogous process in humans, 
guanine in codon 248 gave a smaller extent of oxidation (Table 2.2) than codon 243. 
According to the p53 database,30 the mutation frequency ratio of codons 248/243 is 24, 
248/244 is 7, 248/245 is 2. Our ratios of relative amounts of oxidation by catechol/Cu2+/NADPH 
for codons 248/243 was 1.9, and for codons 248/244 was 1.3, which are smaller than the mutation 
ratios. While we would not expect exact numerical correspondence in codon reactivity and 
44 
 
mutation frequency, the lower reactivity ratios involving guanine in codon 243 may be related to 
it being the first guanine in our exon 7 oligonucleotide and more reactive due to its proximity to 
the end of a strand.44,62 Also, the guanine in codon 248 (CGG) is a CpG site. In vivo, all cytosines 
in CpG sites are methylated, which may increase the reactivity and mutation frequency of the 
neighbor guanine in tumors.39,45,63 For 248/245, the oxidation reactivity ratio was 4.1, which is 
larger than that for mutations. This could be related to the first guanine in codon 245 (GGC) being 
a CpG site, making the guanine more reactive in vivo, resulting in a smaller mutation ratio. 
The ratio of relative amounts of oxidation for codons 248/243 was 0.5 from Fenton’s reagent 
oxidation, which is much lower than that in the database. Fenton’s reagent is just an oxidant, not a 
carcinogen, and may simply oxidize the most accessible guanine with lowest oxidation potential 
in the sequence. The guanine in codon 243 (ATG) is close to the end of the fragment, adjacent to 
AT sequence, and may be more exposed due to a partially unwound duplex with fewer hydrogen 
bonds.44,62 Thus, the guanine in codon 243 may be more reactive in the fragment than the guanine 
in codon 248 (CGG) under in vitro condition. 
Oxidations of guanines at codon 245 (GGC), 246 (ATG), 248 (CGG), and 249 (AGG) were 
observed in isotopic labeled guanines in oligonucleotides.39 Two distinct sites, first guanine in 
codon 245 (GGC) and first guanine in codon 248 (CGG) had the highest oxidation percentage at 
18.7% and 14.2 %, compared to our values 2.6 % and 10.7 %, respectively. This may because both 
guanine sites of highest reactivity had an identical sequence context MeCGG with a methylated 
cytosine on the 5’ side. In our exon 7, the cytosine is non-methylated, and was less easily oxidized.  
Another important observation is the single major peak for oxidized Fragment 1 with 
Fenton’s reagent (Fig. 2.8A), as opposed to four major peaks for oxidized Fragment 1 with 
catechol/Cu2+/NADPH (Fig. 2.2A), suggesting Fenton’s reagent is more specific towards DNA 
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oxidative damage in our system. Several reports indicated that free hydroxyl radical caused DNA 
damage with no marked site specificity.64 ,65 But some investigations show iron (II) binding to 
phosphate groups and a guanine N-7 moiety first, with subsequent oxidative damage of dG, 
oligomers, and calf-thymus DNA in solution.66-68 
Docking studies showed that 35 out of 50 conformations of exon 7 oligonucleotide had Fe2+ 
docked between the fourth and fifth guanines in Fragment 1 (Fig. 2.10, Table 2.3), somewhat 
consistent with Fe2+ binding weakly at a specific guanine prior to the actual oxygen transfer leading 
to 8-oxodG. However, catechol (Fig. 2.11) was found to bind more strongly at multiple positions, 
including the fourth, fifth, sixth, eighth, and thirteenth guanines, which correlates with 
experimental results showing multiple products (Fig. 2.2, Table 2.2). Other possible ROS reactants 
in the catechol reaction also had multiple preferred binding positions on the exon 7 oligonucleotide 
(Table 2.3). Thus, the molecular modelling results are consistent with the broader codon specificity 
found in catechol-induced DNA oxidation. 
2.6 Conclusion 
We describe above a LC-MS/MS methodology to directly sequence and quantify the 
oxidation sites on ds-oligonucleotides of >20 bp. The high oxidation frequency at codon 244 and 
248 with catechol/Cu2+/NADPH, a model for quinoid drug metabolites, coincides with high 
mutation frequency of the p53 gene in lung and other cancers. Fenton’s reagent specificity in 
oxidation may be consistent with binding of a key oxidizing component on the oligonucleotide 
near the oxidation site before subsequent oxygen transfer to guanines. On the other hand, multiple 
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Chapter 3 Organ-Specific Screening for Protein Damage Using Magnetic Bead Bioreactors 
and LC-MS/MS 
3.1 Abstract 
A new 96-well plate methodology for fast, enzyme-multiplexed screening for metabolite-
protein adducts was developed. Magnetic beads coated with metabolic enzymes were used to make 
potentially reactive metabolites that can react with test protein in the wells, followed by sample 
workup in multiple 96-well filter plates for LC-MS/MS analysis. Incorporation of human 
microsomes from multiple organs and selected supersomes of single cyt P450 enzymes on the 
magnetic beads provided a broad spectrum of metabolic enzymes. The reacted protein was then 
isolated, denatured, reduced, alkylated, digested, and peptides collected in a sequence of 96-well 
filter plates for analysis). Method performance was evaluated by trapping acetaminophen reactive 
metabolite N-acetyl-p-benzoquinoneimine (NAPQI) with human glutathione S-transferase pi 
(hGSTP) as a model target protein. Relative amounts of acetaminophen metabolite and hGSTP 
adducts were compared with ten different cyt P450 enzymes. Human liver microsomes and 
CYP1A2 supersomes showed the highest bioactivation rate for adduct formation, in which all four 
cysteines of hGSTP reacted with NAPQI. This method has the potential for fast multi-enzyme 





Protein damage by drugs or pollutants most often involves bioactivation to a reactive 
electrophilic metabolite followed by reaction with a nucleophilic moiety on proteins.1-3 these 
metabolite reactions on proteins can change or destroy protein functions or provoke an antigen 
response, resulting in organ toxicity in humans.4,5 Drug-protein adducts are often monitored in the 
pharmaceutical industry by using radioisotope-tracers in vitro assays.6 Other methods include 
enzyme-linked immunosorbent assay and Western blots, and liquid chromatography-mass 
spectrometry7,8 that have not implemented multiplexed enzyme or magnetic bead approaches. 
Liquid chromatography-mass spectrometric (LC-MS) proteomic analysis is a powerful tool 
to detect protein modifications.9-11 Typical shotgun proteomics starts with digestion of proteins in 
the mixture and separation of resulting peptides by HPLC, then identifies the peptides by tandem 
MS. A reliable, highly parallel sample preparation methodology to facilitate multiple-enzyme 
protein damage screening would be a valuable tool in molecular toxicity assessment and improve 
cost-effectiveness.12-14 
96-Well filter plates (96FASP) are commonly used in protein sample preparation methods14,15 
to accomplish buffer-exchange, denaturation, reduction, alkylation, and digestion. The weakness 
of sample preparation in this format is low centrifugation speed, limited to ~2,000 × g. Therefore, 
many washing steps with centrifugation take 4-6 hrs before digestion. Protein precipitation with 
acetone under low centrifuge speed in 96-well plates (96PACS) can be used as a faster high 
throughput sample preparation approach. 16  Arul et al. developed automated, high-throughput 
sample preparation for proteins in a 96-well filter plate by using vacuum pressure without 
centrifugation or transfer of the filter plate (4-5 hrs before digestion).12, 17  In this paper, we 
modified this approach for metabolite-protein reaction studies by first using enzyme-coated 
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magnetic beads to generates metabolites from a test chemical and then achieving buffer-exchange, 
denaturation, reduction, and alkylation on a filter plate under vacuum to decrease preparation time 
to ~2 hrs before digestion (Scheme 3.1). 
Acetaminophen (APAP), a common analgesic,18 was chosen to investigate drug-induced 
protein damage, a leading cause of acute liver failure in APAP users.19 After being absorbed by 
the gastrointestinal tract, most acetaminophen is converted to nontoxic glucuronide 
(acetaminophen-gluc) and sulfate (acetaminophen-sulf) metabolites by UDP-
glucuronosyltransferases and sulfotransferases. However, 5-9 % of acetaminophen is oxidized to 
N-acetyl-p-benzoquinoneimine (NAPQI) catalyzed by cytochrome P450 (cyt P450) enzymes.20,21 
Usually, NAPQI is rapidly detoxified by glutathione (GSH), but in situations of GSH deficiency, 
such as acetaminophen overdose or long-term use, excess NAPQI reacts with cysteine residues in 
proteins, causing cell death and toxicity in liver.22,23 Human glutathione S-transferase pi (hGSTP), 
the most effective enzyme catalyzing GSH conjugation with electrophiles, is one of the binding 
target proteins for excess NAPQI. 24 -26We previously identified and detected hGSTP-NAPQI 
adducts by using magnetic beads (MBs) coated with cyt P450 2E1 as bioreactors.27 In the present 
paper, we extend this approach to multiple organ microsomal and supersomal enzyme sources to 
evaluated relative amounts of NAPQI-GSH conjugate. The chemically modified positions of 
NAPQI on hGSTP were identified, and relative amounts of reacted peptides were compared using 
a in a 96 well plate sample workup format developed for LC-MS/MS analysis (Scheme 3.1). All 
four cysteines (Cys-14, Cys-47, Cys-101, Cys-169) in hGSTP were found to react with NAPQI 
for the first time, and form 3-(cysteine-S-yl)-acetaminophen adducts. Liver and lung microsomes 
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and CYP1A2 supersome were the most effective enzyme sources for bioactivation of 
acetaminophen and damage to hGSTP.  
Scheme 3. 1 Bioreactor magnetic beads in a 96-well plate followed by sample treatment and LC-
MS/MS sequencing to determine modification sites and quantifying relative amounts of 
modifications. (A) Magnetic beads coated with cyt P450 enzymes coupled to NADPH 
regeneration in a 96-well plate to convert APAP to NAPQI that reacted with hGSTP. (B) 
Solutions of modified hGSTP were separated from MBs and transferred to 96-well filter plate. 
(C) Modified hGSTP was reduced and alkylated. (D) Modified hGSTP was digested, and 
peptides were filtered down to a new plate. (E) LC-MS/MS analysis. The center panel shows a 
96-well plate with a possible experimental reaction plan. 
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3.3 Experimental Section 
3.3.1 Chemicals and Materials 
Carboxylated magnetic beads (MB, 1 µm diam., 20 mg/mL) were from Polysciences, Inc. 
Glutathione S-transferase (GST) from human placenta was from Sigma-Aldrich. PierceTM trypsin 
protease, PierceTM Glu-C protease, PierceTM chymotrypsin protease (TLCK treated) were from 
ThermoFisher Scientific. Reduced glutathione (GSH), acetaminophen, glucose 6-phosphate (G6P), 
glucose 6-phosphate dehydrogenase (G6PDH), nicotinamide adenine dinucleotide phosphate 
(NADP+), urea, dithiothreitol (DTT), iodoacetamide (IAA), poly(diallyldimethylammonium 
chloride) (PDDA), poly(sodium 4-styrenesulfonate) (PSS), myoglobin from horse heart were from 
Millipore Sigma. Human Liver microsome (HLM), human lung microsome (HLuM), human 
kidney microsome (HKM), and human intestine microsome (HIM) were purchased from Sekisui 
XenoTech, LLC. Human supersomes 2A6, 3A5, 3A4, 2E1 (Cytochrome P450 + Cytochrome c 
Reductase + Cytochrome b5) and human supersomes 1A2, 1B1 (Cytochrome P450 + Cytochrome 
c Reductase) were from CORNING. Greiner 96 well plates, polypropylene was from Millipore 
Sigma. AcroPrep advance 96 well filter plates for ultrafiltration, OmegaTM membrane 3K MWCO 
was from Pall corporation. 
3.3.2 Magnetic Beads Bioreactor Assembly 
40 µL of magnetic particles was dispersed in 160 µL of 10 mM Tris buffer (pH 7.4, 10 mM 
NaCl). 200 µL PDDA (2 mg/mL, 50 mM NaCl) was added drop wisely followed by a 20 min 
assembly to coat the negative charged surface with positively charged polycations. The magnetic 
particles are pulled towards the magnet. Then, the supernatant was discarded, particles were 
washed with Tris buffer twice to remove loosely bound polycations, and dispersed into 200 µL 
Tris buffer. The same assembly and wash steps were repeated for polyanion PSS (3 mg/mL, 50 
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mM NaCl) and human microsomes or supersomes film growth. The final architecture on the 
magnetic bioreactors was MP/PDDA/PSS/PDDA/Microsome or Supersome. 
3.3.3 Metabolite Formation 
The magnetic bioreactors were incubated with 1 mM acetaminophen, 1 mM GSH, and 
NADPH regeneration system (10 mM G6P, 1 mM NADP+, 1 U/mL G6PDH enzyme, 1 mM MgCl2) 
in a total volume of 200 µL Tris buffer. After incubation at 37 C for 1h, the reaction was 
terminated by magnetic separation. The solutions were transferred to 96-well OmegaTM membrane 
3K MWCO filter plate, filtered under vacuum, and spiked with 0.14 µM of N2-benzolyguanosine 
as an internal standard before LC-MS/MS analysis. All reactions were done in triplets. 
3.3.4 Protein Adducts Formation 
The magnetic bioreactors were incubated with 1 mM acetaminophen, 100 µg pretreated 
hGSTP, 2 mM DTT and NADPH regeneration system (10 mM G6P, 1 mM NADP+, 1U/mL 
G6PDH enzyme, 1 mM MgCl2) in a total volume of 200 µL Tris buffer. After incubation at 37 C 
for 12h, the reaction was terminated by magnetic separation. The solutions were transferred to 96-
well OmegaTM membrane 3K MWCO filter plate. Control experiment was done in the same 
condition without adding acetaminophen. All reactions were done in triplets. 
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3.3.5 Sample Preparation 
All the sample treatments were done under vacuum. Protein denaturation, disulfate group 
reduction and thiol group alkylation were achieved while solutions were passing through the filter 
membrane. The vacuum was set at – 15 inHg, and the solution took 30 min to pass through the 
filter membrane. A 96-well plate cover was put under the plate filter to collect the waste. Firstly, 
the samples were washed with 100 µL 50 mM ammonium bicarbonate (pH 8.5). 3 µg of horse 
heart myoglobin was added to each well as an internal standard. Proteins denaturation and 
reduction were carried out by adding 100 µL of 8 M Urea and 20 mM DTT. The free thiol group 
on cysteine residues were then alkylated by adding 100 µL of 20 mM IAA in dark. The samples 
were washed twice with 100 µL ammonium bicarbonate, then a new 96-well plate was changed 
under the filter plate. The samples were digested by MS grade trypsin or chymotrypsin or Glu-C 
in a protease/protein (w/w) ratio of 1:25 for 16 hrs. The digestion was stopped by adding 4 µL of 
10 % formic acid. The digested peptides were filtered out through the filter plate for LC-MS/MS 
analysis (Scheme 3.2). 





LC-MS/MS analysis was done on a Thermo Scientific Dionex Ultimate 3000 UHPLC 
system interfaced to a Thermo Scientific TSQ Quantiva triple quadrupole mass spectrometer. For 
the analysis of metabolites, the samples were separated on a C18 reversed phase analytical column 
(Hypersil GOLD, 0.3 × 150 mm, 3 µm, Thermo Scientific) with gradient elution (Table 3.1). The 
metabolites identification was done in the product ion scan mode with collision energy 20 V for 
GSH-acetaminophen (m/z 457.2). Multiple reaction monitoring (MRM) mode was used to 
quantify the metabolites formation. The mass transitions were listed in Table 3.2. Key parameters 
of MS instrument were set as ion source type = H-ESI , spray voltage = 3800 V, sheath gas = 15 
Arb, aux gas = 7 Arb, sweep gas = 4 Arb, ion transfer tube temperature = 300 C, vaporizer 
temperature = 30 C. MRM properties were set as cycle time = 1 s, Q1 resolution (FWHM) = 0.7, 
Q3 resolution (FWHM) = 0.7, CID gas = 1.5 mTorr. 










0 6 1 0 15 1 
7 6 1 7 15 1 
16 6 50 19 15 30 
16.5 6 90 19.5 15 90 
21 6 90 21 15 90 
21.5 6 1 21.5 15 1 
25 6 1 25 15 1 
Table 3. 1 UHPLC gradient used for metabolite and tryptic peptide identification and quantitation. 
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Table 3. 2 MRM transitions and parameters used in the metabolite and peptide quantification. 
Metabolites CE, V Mass transition, m/z Role 
NAPQI-GSH 18 457.2→328.3 Quantitation 
20 457.2→382.2 Confirmation 
N2-
benzolyguanosine 
28 388.1→238.1 Quantitation 
35 388.1→256.1 Confirmation 
Peptides CE, V Mass transition, m/z Role 
CAALR 12.4 295.7→359.2 (y3) Quantitation 
 12.4 295.7→430.3 (y4) Confirmation 
CAALR 13.9 341.7→359.2 (y3) Quantitation 
 13.9 341.7→430.3 (y4) Confirmation 
ASCLYGQLPK 21.6 568.8→705.4 (y6) Quantitation 
 21.6 568.8→542.3 (y5) Confirmation 
ASCLYGQLPK 23.2 614.8→705.4 (y6) Quantitation 
 23.2 614.8→542.3 (y5) Confirmation 
LFTGHPETLEK 23.9 636.3→716.4 (y6) Quantitation 
 23.9 636.3→910.5 (y8) Confirmation 
RCKY 13 313.7→182.1 (y1) Quantitation 
 13 313.7→445.2 (b3) Confirmation 
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RCKY 14.6 359.7→182.1 (y1) Quantitation 
 14.6 359.7→537.3 (b3) Confirmation 
KKHGTVVL 17.3 441.3→625.4 (y6) Quantitation 
 17.3 441.3→753.5 (y7) Confirmation 
VLAPGCLD 16.9 422.7→213.2 (b2) Quantitation 
 16.9 422.7→561.2 (y5) Confirmation 
VLAPGCLD 18.2 468.7→213.2 (b2) Quantitation 
 18.2 468.7→653.3 (y5) Confirmation 
IAAKYKE 16.3 411.7→638.4 (y5) Quantitation 
 16.3 411.7→439.2 (y3) Confirmation 
 
For peptides separation, a Jupiter C18 column (0.5 × 150 mm, 5 µm, Phenomenex) in 
gradient elution (Table 3.1) was used. In both separation, 99 % water, 1 % ACN (0.1 % formic 
acid) was used as solvent A and 99 % ACN, 1 % water (0.1 % formic acid) was used as solvent B. 
The adducted peptide identification was done in the product ion scan mode with collision energy 
14 V for adducted peptide 14-18 (m/z 341.7), 23 V for adducted peptide 45-54 (m/z 614.8), 20 V 
for adducted peptide 100-103 (m/z 359.7), 21 V for adducted peptide 164-171 (m/z 468.7). 
Multiple reaction monitoring (MRM) mode was used to quantify the adducted peptides. An open-
source bioinformatics tool, Skyline28, was used to generate the mass transition list for MRM. All 
mass transitions are listed in Table 3.2. The MRM data were then imported back to Skyline to 
obtain peak areas of peptides. Key parameters of MS instrument were set as ion source type = H-
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ESI, spray voltage = 3900 V, sheath gas = 20 Arb, aux gas = 7 Arb, sweep gas = 2 Arb, ion transfer 
tube temperature = 300 C, vaporizer temperature = 30 C. MRM properties were set as cycle time 
= 1s, Q1 resolution (FWHM) = 0.7, Q3 resolution (FWHM) = 0.7, CID gas = 1.5 mTorr. 
3.4 Results 
The protein hGSTP was reacted with acetaminophen in microwells catalyzed by magnetic 
beads bioreactor coated with different cyt P450 enzyme sources. Ten different CYP enzyme 
sources were used, four microsomal enzymes including human liver microsomes (HLMs), human 
lung microsomes (HLuMs), human kidney microsomes (HKMs), and human intestine microsomes 
(HIMs); four CYP supersomes that contain major enzymes in specific organs, including CYP1A2 
(liver), CYP2A6 (lung), CYP1B1 (kidney), and CYP3A5 (liver and intestine);29,30,31 two other 
CYP supersomes that are responsible for acetaminophen metabolism, CYP2E1 and 
CYP3A4.27,32,33 The bioactivation of acetaminophen was driven by NADPH regeneration system 
dissolved in solution to form its metabolite NAPQI, which then reacted with hGSTP in solution. 
The modified hGSTP was isolated from bioreactor MBs by a magnet, then denatured, reduced, 
alkylated and digested on a filter plate. The modified positions of NAPQI on hGSTP was located 
by LC-MS/MS. Fragmentation of protease digested peptides typically show cleavage of peptide 
bonds, enabling sequencing of the peptide and identification of modified amino acids.34-36 The 
relative amount of metabolite formation and modified peptides were also evaluated. (Scheme 3.1) 
3.4.1 Metabolite Formation  
The formation of NAPQI was identified by adding GSH in solution to form NAPQI-GSH 
conjugate. Different cyt P450 enzymes were deposited onto magnetic beads to form bioreactor 
beads by using alternate electrostatic layer-by-layer assembly in order to catalyze metabolite 
formation.37,38 GSH in the incubation system was used to trap the reactive metabolite NAPQI 
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following generation, and the bioreactor beads were removed by a magnet. Product ion spectrum 
of NAPQI-GSH conjugate at m/z 457.2 shows typical fragmented ion patterns at m/z 328.3, 382.2, 




Figure 3. 1 LC-MS/MS results for NAPQI-GSH conjugate. (A) Product ion spectrum of 
NAPQI-GSH conjugate at m/z 457.2 with collision energy 20 V; (B) Extracted ion 
chromatogram (XIC) for MRM mass transition m/z 457.2 to m/z 328.3. 
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Extracted ion chromatography (XIC) for MRM mass transition m/z 457.2 to 328.3 shows 
the NAPQI-GSH conjugate eluted at 13.7 min (Figure 3.1B). Detection of the NAPQI-GSH 
conjugate confirmed NAPQI metabolite formation.27,39  
Relative amounts of NAPQI-GSH conjugates were measured by LC-MRM using N2-
benzolyguanosine as an internal standard (Figure 3.2). Detailed MRM mass transitions are listed 
in Table 3.2. Figure 3.4 shows relative amounts of NAPQI-GSH conjugate obtained for different 
enzyme sources. Results were normalized to the amounts of enzymes on the magnetic beads 
(estimated by bicinchoninic acid (BCA) assay with Micro BCA Protein Assay, Figure 3.3), 
concentration of acetaminophen used, and time of reaction. The order of bioactivation activity of 
different organ microsomes was found as HLM ≈  HLuM > HIM > HKM. The order of 




Figure 3. 2 The representative MRM chromatograms containing two transitions of each 










Figure 3. 3 Micro BCA protein assays for (A) standard human liver microsome (HLM), (B) 
standard cytochrome P450 1A2. 
Figure 3. 4 NAPQI-GSH conjugate formation with different enzymes. Relative amounts of 
NAPQI-GSH conjugate {µg of protein}-1, {mM acetaminophen}-1, h-1 formed as ratios of area 
under NAPQI-GSH peak to that of internal standard after incubation for 1hr at 37 C. 
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3.4.2 Protein Adduct  
To investigate metabolite-protein adducts, enzyme-bioreactor magnetic beads were 
incubated with acetaminophen and hGSTP in solution. The reaction was terminated by removing 
bioreactors with a magnet, leaving adducted and non-adducted hGSTP in solution. The solution 
was transferred to a new 96-well filter plate for denaturation, reduction, alkylation, and protease 
digestion. The purpose of alkylation is to protect the free sulfhydryl groups from forming disulfide 
bonds again. Horse heart myoglobin was added before denaturation as an internal standard. Three 




Figure 3. 5 Product ion spectrum of (A) NAPQI-adducted peptide CAALR with m/z 341.7; 
(B) NAPQI-adducted peptide ASCLYGQLPK with m/z 614.8 by trypsin digestion. The b 






Figure 3. 6 Product ion spectrum of (A) unadducted peptide CAALR with m/z 295.7; (B) 
unadducted peptide ASCLYGQLPK with m/z 568.8. 
Figure 3. 7 Extracted ion chromatograms (XIC) for NAPQI-adducted and unadducted 
CAALR, NAPQI-adducted and unadducted ASCLYGQLPK, and peptide LFTGHPETLEK 
from internal standard by trypsin digestion. 
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The mass of a NAPQI-adducted peptide will increase by 149.048, which is the monoisotopic 
mass of NAPQI. Adducted peptides CAALR representing position 14 to 18 and ASCLYGQLPK 
at position 45 to 54 in trypsin digested hGSTP were found. The MS/MS spectrum of adducted 
peptide CAALR with m/z 341.7 (Figure 3.5A) shows unchanged y1, y2, y3, y4 ions, and increased 
b2 and b3 ions, which indicates Cys-14 was adducted. The MS/MS spectrum of adducted peptide 
ASCLYGQLPK with m/z 614.8 (Figure 3.5B) shows increased b3, b5, b6 ions, also increased y8, 
y9 ions indicating adducted Cys-47. The unadducted peptide 14-18 with m/z 295.7 and 45-54 with 
m/z 568.8 were found in unreacted control samples. The MS/MS spectra of unadducted peptide 
14-18 and 45-54 are shown in Figure 3.6. 
 
Figure 3. 8 The representative MRM chromatograms containing two transitions for a single 
tryptic peptide for quantitation purpose. 
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LC-MRM MS conditions were optimized so that the adducted and unadducted peptides were 
well separated to provide a good basis for quantitation (Figure 3.7). Two MRM transitions were 
used to identify each peptide and the one with larger peak area was used for quantitation (Figure 
3.8, Table 3.2). M/z transitions 341.7 to 359.2, 295.7 to 359.2 were used for adducted and 
unadducted CAALR; m/z transitions 614.8 to 705.4, 568.8 to 705.4 were used for adducted and 
unadducted ASCLYGQLPK; m/z 636.3 to 716.4 was used for internal standard LFTGHPETLEK. 
Relative amounts of adducted peptides were estimated as ratio of peak area of adducted peptide to 
that of internal standard divided by ratio of peak area under unadducted peptide to that under 
internal standard. Figure 3.9A shows the relative amounts of adducted peptide 14-18 containing 
Cys-14 with different enzyme sources. Results were normalized by the amounts of enzyme 
proteins on the magnetic beads (estimated by Micro BCA Protein Assay, Figure 3.4), concentration 
of acetaminophen used, and time of reaction. The order of bioactivation activity of different organ 
microsomes was found as HLM > HLuM ≈ HKM > HIM. The order of bioactivation activity of 
different supersomes was 1A2 > 2E1 > 3A4 > 2A6 > 3A5 > 1B1. For relative amount of adducted 
peptide 45-54, the order of bioactivation activity of different enzymes was found as similar with 
adducted peptide 14-18, but with 3A5 larger than 3A4 and 2A6. 
Figure 3. 9 NAPQI-adducted peptides formation with different enzymes. Relative amounts 




Chymotrypsin was used to detect NAPQI modification on Cys-101. Figure 3.10A shows 
extracted ion chromatograms (XIC) for adducted and unadducted peptides 100-103, and internal 
standard KKHGTVVL. The MS/MS spectrum of adducted peptide 100-103 (RCKY) with m/z 
359.7 (Figure 3.10B) shows unchanged y1, y2, b1 ions, and increased b2, b3, and y3 ions, which 
indicates Cys-101 was adducted. The unadducted peptide 100-103 with m/z 313.7 was found in 
unreacted control samples. The MS/MS spectra of unadducted peptide 100-103 are shown in 
Figure 3.11. Relative amounts of adducted peptide 100-103 was estimated by peak areas under 
MRM peaks of adducted and unadducted peptides similarly with peptide 14-18. Detailed mass 
transitions were listed in Table 3.2 and MRM chromatograms in Figure 3.12. The order of 
bioactivation activity of different organ microsomes was found as HLM ≈ HLuM > HKM > HIM. 
The order of bioactivation activity of different supersomes was 1A2 > 3A4 > 2E1 ≈ 2A6 >3A5 > 
1B1 (Figure 3.13A).  
Figure 3. 10 (A) Extracted ion chromatograms (XIC) for NAPQI-adducted and unadducted 
RCKY, and peptide KKHGTVVL from internal standard; (B) Product ion spectrum of 




Glu-C was used to detect NAPQI modification on Cys-169. Figure 3.14A shows extracted 
ion chromatograms (XIC) for adducted and unadducted peptides 164-171, and internal standard 
IAAKYKE. The MS/MS spectrum of adducted peptide 164-171 (VLAPGCLD) with m/z 468.7 
(Figure 3.14B) shows unchanged y1, y2, b2, b3, and b5 ions, and increased y3, y5, y6, and b6 ions, 
which indicates Cys-169 was adducted. The unadducted peptide 164-171 with m/z 422.7 was 
found in unreacted control samples. The MS/MS spectra of unadducted peptide 164-171 are shown 
in Figure 3.11B. Relative amounts of adducted peptide 164-171 was estimated by peak areas under 
MRM peaks of adducted and unadducted peptides similarly with peptide 14-18. Detailed mass 
transitions were listed in Table 3.2 and MRM chromatograms in Figure 3.15. The order of 
bioactivation activity of different organ microsomes was found as HLuM > HLM > HKM ≈ HIM. 
The order of bioactivation activity of different supersomes was 1A2 > 2E1 > 2A6 > 3A4 > 3A5 > 
1B1 (Figure 3.13B). 
Figure 3. 11 Product ion spectrum of (A) unadducted peptide RCKY with m/z 313.7; (B) 








Figure 3. 12 The representative MRM chromatograms containing two transitions for a single 
Chymotrypsin digested peptide for quantitation purpose. 
Figure 3. 13 NAPQI-adducted peptides formation with different enzymes. Relative amounts of 
NAPQI-adducted peptide (A) RCKY and (B) VLAPGCLD {µg of protein}-1, {mM 
acetaminophen}-1, h-1 formed as ratio of area under NAPQI-adducted peptide peak to that of 






Figure 3. 15 NAPQI-adducted peptides formation with different enzymes. Relative amounts of 
NAPQI-adducted peptide (A) RCKY and (B) VLAPGCLD {µg of protein}-1, {mM 
acetaminophen}-1, h-1 formed as ratio of area under NAPQI-adducted peptide peak to that of 
internal standard over ratio of area under unadducted peptide peak to that of internal standard in 
control. 
Figure 3. 14 The representative MRM chromatograms containing two transitions for a single Glu-




Results above demonstrate a new, cell-free in vitro assay that metabolizes test compounds 
using a range of desired metabolic enzymes to produce reactive metabolites that react with proteins 
and enables protein sample preparation for analysis by LC-MS/MS. The magnetic bead bioreactors 
coated with metabolic enzymes facilitate investigation of a wide range of cyt P450s enzymes and 
greatly simplify separation of reacted proteins from the enzyme. The sample preparation method 
using 96-well filter plate under vacuum shortens the sample preparation time and avoids transfer 
of the sample plate. This method is simple, fast, high-throughput, and facilitates mapping of 
modified positions on proteins. 
All the enzyme sources used led to the same metabolite formation, but at different rates. The 
largest amount of NAPQI was formed when human liver microsomes and human lung microsomes 
were used (Figure 3.3), which correlates with liver as the major damage site in acetaminophen 
overdose.40 Human kidney and intestine microsomes had low bioactivation rates (Figure 3.3). 
Among the supersomes used, cyt P450 1A2 produced the largest amount of NAPQI, followed by 
cyt P450 2E1 and 3A5. cyt P450s 1A2, 2E1, and 3A5 are strongly expressed in human liver31,41 
and our results are fully consistent with reports that cyt P450s 1A2 and 2E1 are major factors for 
acetaminophen bioactivation in humans.26,42  Cyt P450 3A4 provided moderate bioactivation, 
while  activities of cyt P450s 2A6 and 1B1 were quite low.  
Results in Figure 3.5 show that two adducted positions, Cys-14 and Cys-47 on hGSTP were 
observed by using trypsin digestion. The adduction by NAPQI at Cys-47 is consistent with other 
reports, 43-45 and Cys-47 is highly reactive toward electrophiles due to its relatively low pKa and 
accessibility.46,47 Adducted Cys-101 and Cys-169 were not found by using trypsin as digestion 
protease. With trypsin digestion, Cys-101 is expected to exist as a dipeptide CK, which may have 
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low retention on reverse phase chromatography. The peptide containing Cys-169 consists of 42 
amino acids from residue 141 to 182, which is too large to be detected.44 Chymotrypsin and Glu-
C were used to detect modifications on Cys-101 (Figure 3.10) and Cys-169 (Figure 3.14). 
Modifications of NAPQI on Cys-101 was confirmed in the previous report43, and on Cys-169 was 
reported for the first time.  
The results of relative amounts of NAPQI adducted peptides showed CYP1A2 gave the 
highest adducted peptide formation, followed by cyt P450 2E1 (Figure 3.9, 3.13). Among 
microsomes, human liver microsomes gave more adducted peptides than others. Results are 
consistent with amounts of NAPQI metabolite formation (Figure 3.3), i.e., the more metabolite 
formed, the more adducted peptide formation. Also, results confirm cyt P450 1A2 and 2E1 as 
major enzymes responsible for acetaminophen liver failure.26,42  
3.6 Conclusion 
We describe above a new high-enzyme throughput sample preparation method coupled with 
enzyme-coated magnetic bead bioreactors that facilitates bioactivation of drugs to reactive 
metabolites and reaction with proteins to characterize specific damage to the proteins. All 4 
cysteines in hGSTP (Cys-14, Cys-47, Cys-101, and Cys-169) reacted with the acetaminophen 
metabolite. This new methodology is suitable for organ-specific analysis of protein damage by 
metabolites of drugs and other chemicals. The method provides exact sites and relative amounts 
of adduct formation compared with traditional radioisotope or immunological techniques, and also 
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Chapter 4  LC/MS Quantitation of Biotherapeutic Monoclonal Antibody Glycoforms 
4.1 Abstract 
Therapeutic biotechnology products, such as monoclonal antibodies (mAbs) are subject to 
reactions during cell culture processing, purification, and storage process. Multiple product 
variants are formed which results in heterogeneity of mAbs. N-glycosylation is one of the most 
common post-translational modifications. Glycan structures attached on the CH2 domain of the Fc 
region of immunoglobulin G (IgG) are essential for its functionalization, but their effects on 
clearance is less clear. Clearance of therapeutic antibodies is important as it impacts efficacy. Here, 
we are developing quantitative methods to investigate the impact of Fc glycans on the clearance 
of a therapeutic humanized IgG1 monoclonal antibody by LC-MS/MS. The methods consisted of 
an immunocapture purification followed by tryptic digestion and LC-MS/MS analysis of surrogate 
peptides associate with glycosylation sites. Two methods were developed and compared, one is 
establishing calibration curves with glycopeptides intensities versus concentrations without 
internal standards; the other one is dimethyl labelling of tryptic peptides with either d(2)-13C or 
d(0)-formaldehyde and establishing calibration curves with heavily labelled peptides as internal 
standards. Both methods gave similar linearity, LLOQ of dimethyl labelled method was two times 
higher than the unlabeled method. These methods allowed us to assess in vivo changes of all 





Monoclonal antibodies (mAbs) are emerging therapeutic products in the pharmaceutical 
industry for the past decades.1-3 Post-translational modifications occur naturally during antibody 
biosynthesis, purification, and storage process, which results in multiple variants of antibodies.4 
Some variants, such as deamidation, oxidation, and glycosylation, have been reported to have 
significant impact on antibody biological activities. 5 -7  Those modifications are considered as 
critical quality attributes, which must be limited to appropriate level to ensure the drug safety and 
efficacy. 
Glycosylation is one of the most common post-translational modifications of therapeutic 
antibodies. Different levels of terminal galactose residues with fucose core (G0F, G1F, and G2F 
where G represents the number of galactose, F is the fucose core) and some high mannose 
structures are usually attached at the Fc site of recombinant antibodies which are expressed using 
Chinese hamster ovary tissue culture.8-10 The half-life of antibodies in serum is regulated by Fc 
receptor, which is not influenced by the presence of different glycoforms. 11 ,12  But mannose 
receptors have the ability to clear glycoproteins with terminal Mannose.13,14 Thus, the antibodies 
with high mannose structures may clear faster, which would affect the antibody drug efficacy.15 
Glycosylation is considered as one of the quality attributes, which should be assessed in preclinical 
and clinical samples to ensure the drug safety and efficacy.16 In order to check the clearance rate 
of different glycoforms, quantitative methods for glycoforms should be developed, and the 
clearance of various glycoforms should be assessed in preclinical and clinical samples to provide 
quality attributes criticality in the biopharmaceutical manufacturing process. 
Mostly used method for glycoanalysis is released glycans, in which the glycans are released 
from all the glycoproteins, and each glycoform is monitored. 17 - 19  By using this method, 
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information about the originating proteins or the glycosylation sites can not be obtained.20 Another 
commonly used method is intact protein analysis, in which the intact protein containing glycans is 
analyzed. The limitation of this method is that the glycoforms with low abundance could not be 
detected.21 The last method that incorporates the originating proteins and the glycosylation sites is 
analysis of glycopeptides from the Fc region. This method is restricted to relative quantitation due 
to lack of isotopic labeled glycopeptides. The level of a glycopeptide is calculated as response of 
the glycopeptide divided by sum of responses of all glycopeptides from the same peptide.22 
Herein, absolute quantitative methods for therapeutic antibody IgG1 glycopeptides were 
developed using LC-MS/MS. Dimethyl labelling was performed at peptide level after trypsin 
digestion, the labelled glycopeptides were used as internal standards. These developed methods 
can be employed to investigate the clearance of different glycoforms using cynomolgus monkey 
plasma samples from a preclinical pharmacokinetic study. 
4.3 Experiment Section 
4.3.1 Chemicals and Materials 
Monoclonal antibody IgG1 was a proprietary experimental biotherapeutic of Boehringer 
Ingelheim Pharmaceuticals and produced in-house. The goat anti-human IgG was purchased from 
Abcam. Streptavidin magnetic beads (1 µm dia.), TPCK trypsin, and EZ-Link Sulfo-NHS-LC 
Biotinylation kit were obtained from Thermo Scientific. RapiGest SF was purchased from Waters. 
All other chemicals, reagents, and buffer solutions were from MilliporeSigma. 
4.3.2 Biotinylation of anti-human IgG 
Biotinylation of goat anti-human IgG was performed using an EZ-Link Sulfo-NHS-LC 
Biotinylation kit. Anti-human IgG solution (1 mg/mL) was incubated with 20-fold molar excess 
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of biotin at room temperature for 1 hr. Excess biotin was removed by Zeba spin desalting columns. 
HABA assay was used to measure the level of biotin incorporation after removing all traces of 
non-reacted and hydrolyzed biotinylation reagent. The typical biotin corporation was 2-7 biotins 
per anti-human IgG. Then, the biotinylated was diluted to 0.1 mg/mL and stored in -80 C prior to 
use.  
4.3.3 Immunoaffinity Capture 
Stock concentration of mAb IgG1 was 10.21 mg/mL. A series of 50-100,000 ng/mL spiking 
calibration standards were prepared in cynomolgus monkey plasma, the QC samples were prepared 
in the concentrations of 300, 2500, and 75000 ng/mL and stored at -80 C prior to use. The 
immunocapture procedure is similar as previously reports.23,24 20 µL of plasma samples, 75 µL of 
biotinylated anti-human IgG, and 450 µL of Tris buffered saline (25 mM Tris, 150 mM NaCl, pH 
7.2) with 0.1 % Tween 20 (TBS-T) were pipetted into a 96-deep-well polypropylene plate. The 
plate was incubated at room temperature for 2 hrs. A 50 µL aliquot of freshly prepared 5 mg/mL 
magnetic beads were added to each sample and the plate was incubated for another 1.5 hrs. The 
beads were separated, washed three times with 300 µL TBS-T, once with 300 µL water, and then 
eluted with 150 µL of 25 mM HCl on a KingFisher Flex bead handler. (Scheme 4.1) 
4.3.4 Trypsin Digestion 
To the immunocapture eluent, or neat IgG1 solution (30 µg in 150 µL 25 mM HCl), 20 µL 
of 1M Tris-HCl (pH 8.0) was added to neutralize the solution. 10 µL of 0.1% RapiGest and 10 µL 
of 100 mM Tris(2-carboxyethyl)phosphine (TCEP) in 100 mM ammonium bicarbonate were 
added and followed by incubation at 60 C for 1hr. 5 µL of 200 mM iodoacetamide in 100 mM 
ammonium bicarbonate was added to alkylate the free thiol groups at room temperature for 30 min 
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in dark. 10 µL of 6 µg/ µL trypsin was added to each sample and the plate was incubated at 37 C 
overnight. Digestion was quenched by adding 5 µL of 20 % trifluoroacetic acid (TFA). The 
samples were mixed for 40 min at 37 C, then centrifuged at 3800 rpm for 10 min prior for LC/MS 
analysis. 
 
4.3.5 Dimethyl Labelling 
After trypsin digestion, 20 µL of NaBH3CN and 20 µL of d(0)-formaldehyde were added to 
each standard and QC sample well for d(0)-dimethyl labelling. 20 µL of NaBD3CN and 20 µL of 
d(2)-13C-formaldehyde were added to neat digestion sample well for d(2)-13C-dimethyl labelling. 
The plate was incubated and shaken at room temperature for 2 hrs. The resultant reaction mixture 
in each well was then acidified by adding 10 µL of 20 % TFA. 5 µL of the d(2)-13C-dimethyl 
labelled sample was then spiked into each d(0)-dimethyl labelled samples as internal standard. The 
sample plate was then centrifuged and analyzed using UPLC-MS/MS. 
 
Scheme 4. 1 Immunocapture LC-MS Assay Workflow. 
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4.3.6 LC-MS Analysis 
A Waters ACQUITY UPLC coupled with AB Sciex 6600 triple TOF mass spectrometer was 
used for glycopeptide identification. Chromatographic separation was performed using ACQUITY 
UPLC Peptide BEH C18 column (1mm × 50 mm, 1.7 µm, 300 Å) operated at 50 C. Mobile phases 
consisted of (A) water with 0.1 % formic acid and (B) acetonitrile with 0.1 % formic acid running 
at a flow rate of 300 µL/min. The LC gradient was 1 % to 10 % B over 6 min, then to 95 % B over 
0.5 min, and back to 1 % B at 10 min. The mass spectrometer was operated in a positive 
electrospray ionization mode. Key instrument parameters were as follow: +5500 V electrospray 
voltage, 350 ion source temperature, ion source gas 1 with 80, ion source gas 2 with 20, curtain 
gas 35. 
A Waters ACQUITY UPLC coupled with AB Sciex 6500 + triple quadrupole mass 
spectrometer was used for glycopeptide quantitation. Chromatographic separation was performed 
using ACQUITY UPLC Peptide BEH C18 column (1mm × 50 mm, 1.7 µm, 300 Å) operated at 
50 C. Mobile phases consisted of (A) water with 0.1 % formic acid and (B) acetonitrile with 0.1 % 
formic acid running at a flow rate of 15 µL/min. The LC gradient was 6 % to 25 % B over 6 min, 
then to 95 % B over 2 min, and back to 6 % B at 10 min. The mass spectrometer was operated in 
a positive electrospray ionization mode. Key instrument parameters were as follow: +5500 V 
electrospray voltage, 200 ion source temperature, ion source gas 1 with 45, ion source gas 2 with 
35, curtain gas25, 12 collision gas units, and unit resolution on both Q1 and Q3. Multiple reaction 





Methods for the absolute quantitation of therapeutic antibody immunoglobulin G1 
glycoforms were developed using MRM on a QqQ-MS. The synthesized IgG1 was used to study 
the behavior of IgG 1 glycopeptides in MRM experiments and develop methods for the 
quantitative analysis of its glycoforms. The methods were then applied to a pooled monkey plasma 
sample to estabolish calibration curves for each glycopeptide in order to assess in vivo changes of 
glycoforms over duration of a preclinical pharmacokinetic study in cynomolgus monkeys. The 
collison induced dissociation (CID) behavior of the tryptic glycopeptides was first studied using 
TOF-MS. Based on these results, MRM transitions were developed on the QqQ-MS, and the 
instrument parameters were optimized to get the best sensitivity for each glycopeptide. The 
abundance of each glycopeptide was calculated by percentage of peak areas under extracted ion 
chromatograms (XIC) of glycopeptides. The absolute concentrations of each glycopeptide were 
calculated by multiplying the abundance with the concentration of antibody. The calibration curves 
of each glycopeptide were plotted using MRM peak areas versus concentrations of glycopeptides. 
Using this strategy, all the glycopeptides were monitored and quantified simultaneously.  
4.4.1 Identification of glycopeptides 
An IgG 1 standard was subjected to trypsin digestion, and the resulting peptides and 
glycopeptides were analyzed using LC-triple TOF MS/MS to evalute the fragementation behavior. 
The tryptic peptide EEQYNSTYR is the target peptide on Fc region that contains N-glycosylation 
site. Figure 4.1 shows the TOF spectra of G0F, G1F, and Mann5 with +2 and +3 charge. The 
abundance of each glycopeptide was calculated as ratio between sum of peak areas under XIC of 
each isotopic peak for one glycopeptide and sum of peak areas under XIC of all glycopeptides. 
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Results are summarized in Table 4.1. Seven glycopeptides were observed in the sample with G0F 




Figure 4. 1 TOF spectra of glycopeptides. (A) G0F, z = +3; (B) G0F, z = +2; (C) G1F, z = +3; 








Table 4. 1 Structure and abundance of observed glycopeptides. 
Figure 4. 2 Product ion scan spectra of glycopeptides: (A) MS/MS spectrum of G0F-
EEQYNSTYR (m/z 878.68, z = +3); (B) MS/MS spectrum of Mann5-EEQYNSTYR (m/z 
802.65, z = +3). 
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LC-MS analysis with tripleTOF instrument allowed identification of the glycopeptides based 
on the accurate mass and the tandem MS. The fragmentation spectra showed the typical glycan 
fragment ions, corresponding to the small glycan fragments, including m/z 204.08 (HexNAc), 
366.14 (Hex1HexNAc1), 528.19 (Hex2HexNAc1). The MS/MS spectra of two glycopeptides G0F 
and Mann5 are shown in Figure 4.2, and the predicted glycan fragments are clearly visible with 
high intensities. 
Table 4. 2 MRM transitions, optimized CE, DP, and CXP for glycopeptides. 
 
4.4.2 Quantitation of glycopeptides 
In the tandem MS spectra of glycopeptides, m/z 204.08 is the most abundant fragmentation 
ion. The MRM transitions for all the glycopeptides are their precursor ions to 204.08, which are 
listed in Table 4.2. Also, the optimized collision energy (CE), declustering potential (DP), and cell 
exit potential (CXP) for each glycopeptide are included in Table 4.2. 
The chromatograms for glycopeptides obtained from the MRM transitions are shown in 
Figure 4.3. All glycopeptides were eluted from 4.4 to 4.8 min, because the retention was influenced 
Glycoforms MRM pairs CE DP CXP 
G0F 878.68 → 204.08 20 60 10 
G1F 932.70 → 204.08 24 60 20 
Mann5 802.65 → 204.08 36 70 10 
G2F 986.72 → 204.08 36 60 10 
G0 830.00 → 204.08 24 70 10 
G1 884.02 → 204.08 28 60 10 
G0F-N 810.99 → 204.08 24 60 10 
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mostly by the peptide moiety, the variety of glycoforms on the same peptide will not influence the 
retention time a lot. 
 
 
The absolute quantitation of glycopeptides is hard to be achieved due to the lack of 
glycopeptide standards. Here, we calculated the concentrations of each glycopeptide with their 
abundance. The calibration curves were constructed by plotting the MRM peak area under each 
glycopeptide versus their concentrations, which can be obtained in one single run. Figure 4.4 
shows the calibration curves for G0F and Mann5 in monkey plasma. The linear range for G0F is 
17 – 33100 ng/mL; Mann5 is 76 – 15200 ng/mL. Figure 4.5 shows the LC-MS chromatograms for 
G0F and Mann5 in their LLOQ samples. 
 
 










Table 4. 3 Method Qualification 
 
Glycoforms G0F G1F Mann5 
Calibration standard curve range 17-33100 ng/mL 35-35000ng/mL 76-15200 ng/mL 
QC concentrations 
99, 828, 24825 
ng/mL 




QC Intra-batch Precision (%CV) 5.3% – 31.1% 4.7% – 26.6% 6.4% – 19.1% 
QC Intra-batch Accuracy (%RE) -9.2% - 19% -15.7% - 24% -5.0% – 10.9% 
QC Inter-batch Precision (%CV) 15% - 21% 15.6% – 20.3% 13.5% – 14.2% 
QC Inter-batch Accuracy (%RE) -7.1% – 9.5% -9.8% – 10.4% 0.9% – 2.8% 
Figure 4. 5 LC/MS chromatograms of G0F (A) and Mann5 (B) from LLOQ samples. 
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4.4.3 Method Qualification  
Three batches of calibration standards, and quality control (QC) samples were ran on the 
assay to validate the quality of the method. Three different concentration levels of QC samples 
(four duplicates each) were used. The concentrations of QC samples for each glycoform were 
calculated based on IgG 1 concentrations and their abundance. There are two QC concentrations 
for Mann5 since the concentration of Mann5 in low QC sample is lower than LLOQ. Results for 
method qualification are shown in Table 4.3. QC intra-batch precision was calculated as relative 
standard deviation of 4 replicated QC samples in one batch. QC inter-batch precision was 
calculated as relative standard deviation of 12 QC samples in three batches (6 QC samples for 
Mann5). QC intra-batch accuracy was calculated as relative error ((calculated concentration – 
exact concentration)/ exact concentration × 100) of 4 replicated QC samples in one batch. QC 
inter-batch accuracy was calculated as relative error of 12 QC samples in three batches (6 QC 
samples for Mann5). 
4.4.4 Dimethyl Labeling at Peptide Level 
No internal standards were used in the previous quantitation method due to lack of synthetic 
isotopic labeled glycopeptides. Reductive amination of primary amine groups at N-terminal on 
tryptic peptides was performed to generate stable isotope labeled internal standards. As shown in 
Scheme 4.2, for light labeling, d(0)-formaldehyde and sodium cyanoborohydride were used as the 
reagents to add two methyl group on the N-terminal; for heavy labeling, 13C-d(2)-formaldehyde 
and sodium cyanoborodeuteride were used as the reagents to add two deuterated methyl groups on 





4.4.5 Identification of Dimethyl Labeled Glycopeptides 
Two IgG 1 standards were subjected to trypsin digestion, followed by light and heavy 
dimethyl labeling reactions, and the resulting peptides and glycopeptides were analyzed using LC-
triple TOF MS/MS to identify dimethyl labeled glycopeptides. Figure 4.6 shows the TOF spectra 
of light labeled and heavy labeld G0F (A, B), G1F (C, D), and Mann5 (E, F) with +3 charge, which 
indicates the formation of dimethyl labeled glycopeptides. 
4.4.6 Quantitation of Dimethyl Labeled Glycopeptides 
Light labeling was performed on all calibration standard samples after trypsin digestion. 
Heavy labeling was performed on neat IgG 1 solution after trypsin digestion. Finally, same amount 
of heavy labeled sample was spiked into each calibration standard samples for LC-MS analysis. 
MRM transitions used in the quantitation are listed in Table 4.4. The calibration curves were 
constructed by plotting the MRM peak area ratio between light and heavy labeled glycopeptides 
versus their concentrations, which can be obtained in one single run. Figure 4.7 shows the LC-MS 
chromatograms for G0F and Mann5 in their LLOQ samples. Figure 4.8 shows the calibration 
curves for G0F and Mann5 in monkey plasma. The linear range for G0F is 33 – 26480 ng/mL; 
Mann5 is 152 – 12160 ng/mL; G1F is 175 – 35000 ng/mL.  








Figure 4. 6 TOF spectra of dimethyl labeled glycopeptides. (A) light labeled G0F, z = +3; 
(B) heavy labeled G0F, z = +3; (C) light labeled G1F, z = +3; (D) heavy labeled G1F, z = 











 G0F G1F Mann5 
Light Label 887.92 → 204.08 942.13 → 204.08 811.62 → 204.08 
Heavy Lable 890.61 → 204.08 944.82 → 204.08 814.30 → 204.08 














An absolute quantitative method for various IgG1 glycoforms in vivo was developed and 
validated with the linear range 17 – 33100 ng/mL for G0F and 76 – 15200 ng/mL for Mann5. 
Dimethyl labelling at peptide N-terminal served as internal standard was developed, with similar 
linearity, and 2-5 times lower sensitivities. The methods can be used to analyze clearance rate of 
various glycoforms using cynomolgus monkey plasma samples. 
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